Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.49 |
| ▸ | CNR1 | P21554 | 4/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL927881 | 0.89 | CNR2 (0.63) | CNR2CNR1 | |
| SCHEMBL927467 | 0.83 | CNR2 (0.45) | CNR2CNR1ADORA1 | |
| SCHEMBL927375 | 0.79 | CNR2 (0.49) | CNR2CNR1 | |
| SCHEMBL927662 | 0.79 | CNR2 (0.62) | CNR2CNR1ADORA1 | |
| SCHEMBL4094732 | 0.77 | CNR2 (0.79) | CNR2CNR1 | |
| SCHEMBL928157 | 0.75 | CNR2 (0.46) | CNR2CNR1 | |
| SCHEMBL3689708 | 0.68 | CNR2 (0.78) | CNR2CNR1 | |
| SCHEMBL926794 | 0.67 | CNR2 (0.49) | CNR2CNR1 | |
| SCHEMBL4090619 | 0.66 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL3808195 | 0.66 | CNR2 (1.00) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868038-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2011-01-11 | — | — | US | claimed |
| US-20080058307-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-03-06 | — | — | US | claimed |
| US-8598224-B2 | Method for treating cannabinoid receptor related diseases with cannabinoid receptor ligands | ABBVIE INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-20110086838-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-04-14 | — | — | US | disclosed |
| US-7868038-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2011-01-11 | — | — | US | disclosed |
| US-20080058307-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058307-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPSR1 | CNR2 2/4885CNR1 1/4885ADORA1 244/4885 |
| US-20110086838-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPSR1 | CNR2 2/4885CNR1 1/4885ADORA1 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.